Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

International Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Study of the Efficacy and Safety of Goflikicept and Olokizumab as the Second-line Therapy in Patients With Still's Disease

NCT07625384 is registered in ClinicalTrials.gov with R-Pharm International, LLC as lead sponsor.

NCT NCT07625384
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07625384 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
International Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Study of the Efficacy and Safety of Goflikicept and Olokizumab as the Second-line Therapy in Patients With Still's Disease
Lead sponsor
R-Pharm International, LLC
Phase
Phase 3
Overall status
Not yet recruiting
Start date
May 18, 2026
Completion date
July 1, 2028
Enrollment
52 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

still disease